Safety of antirheumatic drug treatment in the elderly

被引：2

作者：

Krueger, K. ^{[1
]}

Strangfeld, A. ^{[2
]}

Kneitz, C. ^{[3
]}

机构：

[1] Rheumatol Praxiszentrum, D-81541 Munich, Germany

[2] Deutsch Rheuma Forschungszentrum DRFZ, Berlin, Germany

[3] Klinikum Sudstadt Rostock, Rheumazentrum, Klin Innere Med 2, Rostock, Germany

来源：

ZEITSCHRIFT FUR RHEUMATOLOGIE | 2014年 / 73卷 / 03期

关键词：

Antirheumatic drugs; Drug treatment; Drug safety; Elderly patients; Drug interactions; ONSET RHEUMATOID-ARTHRITIS; OLDER PATIENTS; YOUNGER PATIENTS; MEDICATION NONADHERENCE; BIOLOGICS-REGISTER; METHOTREXATE; THERAPY; COMORBIDITIES; DISEASE; PATIENT;

D O I：

10.1007/s00393-013-1245-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mainly due to the general demographic changes and decreasing mortality in rheumatic diseases based on therapeutic progress, the proportion of older patients treated by rheumatologists is growing. Drug treatment in the elderly, however, harbors certain risks including age-specific pharmacokinetic features and high rates of multimorbidity and polypharmacy resulting in a risk of drug interactions and adherence problems. Nevertheless, older patients suffering from rheumatic diseases ought to be treated with the same intensity and same targets as the younger counterparts. Bearing all these facts in mind it is a balancing act for rheumatologists to find an optimal treatment for the individual elderly patient. Fear of risks should not lead to hesitant use of drugs leaving these patients alone with treatment deficits, as some studies have suggested.

引用

页码：244 / +

页数：6

共 42 条

[1] Leflunomide Treatment in Elderly Patients with Rheumatoid or Psoriatic Arthritis Retrospective Analysis of Safety and Adherence to Treatment [J].